ARHGEF26

Across TCGA pan-cancer cohorts, ARHGEF26 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ARHGEF26 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ARHGEF26 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF26 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and HNSC are the cancer types where ARHGEF26 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.893	0.300	.007	28	view →
HNSC	DFS	Median	III,IV	0.213	0.684	.001	21	view →
BLCA	OS	Median	All	0.097	0.688	<.001	12	view →
COAD	DFS	Median	IV	0.028	0.488	<.001	11	view →
LUSC	OS	Median	II,III,IV	0.214	0.745	<.001	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	DFS	Median	All	0.219	0.579	.029	6	view →
ESCA	DFS	Median	II,III,IV	0.218	0.524	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ARHGEF26–THYM (OS)

Open the THYM breakdown →